Literature DB >> 27344431

Influence of zoledronic acid on proliferation, migration, and apoptosis of vascular endothelial cells.

M Lang1, Z Zhou2, L Shi3, J Niu4, S Xu4, W Lin4, Z Chen4, Y Wang5.   

Abstract

Bisphosphonates are commonly used to treat malignant tumours that originate in bone. In recent years, with the widespread application of these drugs in chemotherapy, reports have raised concerns about the development of osteonecrosis. Though the mechanism of bisphosphonate-related osteonecrosis of the jaw is not clear, vascular injury resulting from their use has been suggested as a possible cause. This study was designed to explore the influence of zoledronic acid, one of the most common bisphosphonates, on the function and viability of vascular endothelial cells in vitro to try to find possible mechanisms of the action bisphosphonates in osteonecrosis. Endothelial cell proliferation, migration, and apoptosis were examined with MTT assays, scratch tests, and flow cytometry in the presence of zoledronic acid in different concentrations. The relative expressions of protein were also examined by western blot assays, and the significance of the differences among concentrations of the drug were assessed statistically. Concentrations zoledronic acid of 15μmol-150μmol, can dose-dependently inhibit the activity of vascular endothelial cell proliferation and migration, and significantly up-regulate cell apoptosis (p<0.05). Zoledronic acid can inhibit the vascular endothelial cell activities of proliferation and migration, and can up-regulate cellular apoptosis, which suggests that direct inhibition of angiogenesis together with vascular impairment might contribute to the development of osteonecrosis of the jaw.
Copyright © 2016 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bisphosphonate-associated osteonecrosis of the jaw; apoptosis; migration; proliferation; vascular endothelial cell

Mesh:

Substances:

Year:  2016        PMID: 27344431     DOI: 10.1016/j.bjoms.2016.05.030

Source DB:  PubMed          Journal:  Br J Oral Maxillofac Surg        ISSN: 0266-4356            Impact factor:   1.651


  9 in total

Review 1.  Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw.

Authors:  J Chang; A E Hakam; L K McCauley
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

2.  Alendronate-induced Perturbation of the Bone Proteome and Microenvironmental Pathophysiology.

Authors:  Jayoung Kim; Austin Yeon; Sarah J Parker; Muhammad Shahid; Aissatou Thiombane; Eunho Cho; Sungyong You; Hany Emam; Do-Gyoon Kim; Minjung Kim
Journal:  Int J Med Sci       Date:  2021-07-23       Impact factor: 3.738

3.  Bone marrow osteoprogenitors are depleted whereas osteoblasts are expanded independent of the osteogenic vasculature in response to zoledronic acid.

Authors:  Russell Hughes; Xinyue Chen; Keith D Hunter; Jamie K Hobbs; Ingunn Holen; Nicola J Brown
Journal:  FASEB J       Date:  2019-09-06       Impact factor: 5.191

4.  Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB.

Authors:  Si-Yong Gao; Guang-Sen Zheng; Lin Wang; Yu-Jie Liang; Si-En Zhang; Xiao-Mei Lao; Kan Li; Gui-Qing Liao
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

Review 5.  Angiogenesis in the Development of Medication-Related Osteonecrosis of the Jaws: An Overview.

Authors:  Andreas Max Pabst; Maximilian Krüger; Sebastian Blatt; Thomas Ziebart; Roman Rahimi-Nedjat; Elisabeth Goetze; Christian Walter
Journal:  Dent J (Basel)       Date:  2016-12-26

6.  Effect of combined treatment with bisphosphonate and vitamin D on atherosclerosis in patients with systemic lupus erythematosus: a propensity score-based analysis.

Authors:  Kazumasa Ohmura; Masaru Kato; Toshiyuki Watanabe; Kenji Oku; Toshiyuki Bohgaki; Tetsuya Horita; Shinsuke Yasuda; Yoichi M Ito; Norihiro Sato; Tatsuya Atsumi
Journal:  Arthritis Res Ther       Date:  2018-04-17       Impact factor: 5.156

Review 7.  Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials.

Authors:  Henrik Holtmann; Julian Lommen; Norbert R Kübler; Christoph Sproll; Majeed Rana; Patrick Karschuck; Rita Depprich
Journal:  J Int Med Res       Date:  2018-08-09       Impact factor: 1.671

8.  Beta tricalcium phosphate, either alone or in combination with antimicrobial photodynamic therapy or doxycycline, prevents medication-related osteonecrosis of the jaw.

Authors:  Henrique Hadad; Laís Kawamata de Jesus; Ana Flávia Piquera Santos; Henrique Rinaldi Matheus; Letícia Gabriella de Souza Rodrigues; Pier Paolo Poli; Elcio Marcantonio Junior; Fernando Pozzi Semeghini Guastaldi; Carlo Maiorana; Juliano Milanezi de Almeida; Roberta Okamoto; Francisley Ávila Souza
Journal:  Sci Rep       Date:  2022-10-03       Impact factor: 4.996

9.  Parathyroid hormone-related protein inhibits nitrogen-containing bisphosphonate-induced apoptosis of human periodontal ligament fibroblasts by activating MKP1 phosphatase.

Authors:  Di Liu; Juan Du; Jing Sun; Minqi Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.